Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 13Uterine Cervical Neoplasms 9Stomach Neoplasms 9Colorectal Neoplasms 7Fallopian Tube Neoplasms 6Carcinoma, Ovarian Epithelial 6Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Endometrial Neoplasms 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Breast Neoplasms 4Prostatic Neoplasms 3Lung Neoplasms 3Esophageal Neoplasms 3Triple Negative Breast Neoplasms 2Sarcoma 2Rectal Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Appendiceal Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Recurrence 1Peritoneal Neoplasms 1

Interventions

Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Gemcitabine 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Acinar Cell × Irinotecan × Gynecologic × Clear all
NCT04657068 2026-03-18

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Artios Pharma Ltd

Phase 1/2 Recruiting
442 enrolled
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Acinar Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡